1. Home
  2. UVE vs ABUS Comparison

UVE vs ABUS Comparison

Compare UVE & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UNIVERSAL INSURANCE HOLDINGS INC

UVE

UNIVERSAL INSURANCE HOLDINGS INC

HOLD

Current Price

$36.91

Market Cap

957.6M

Sector

Finance

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.56

Market Cap

848.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UVE
ABUS
Founded
1990
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
957.6M
848.8M
IPO Year
1996
2008

Fundamental Metrics

Financial Performance
Metric
UVE
ABUS
Price
$36.91
$4.56
Analyst Decision
Buy
Strong Buy
Analyst Count
1
1
Target Price
$40.00
$5.00
AVG Volume (30 Days)
156.4K
1.2M
Earning Date
04-23-2026
05-14-2026
Dividend Yield
1.97%
N/A
EPS Growth
214.43
55.26
EPS
1.88
0.87
Revenue
$1,603,915,000.00
$14,083,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$2.88
$239.71
P/E Ratio
$20.02
$5.28
Revenue Growth
5.48
128.21
52 Week Low
$21.96
$3.04
52 Week High
$41.96
$5.10

Technical Indicators

Market Signals
Indicator
UVE
ABUS
Relative Strength Index (RSI) 40.68 57.10
Support Level $32.51 $4.16
Resistance Level $41.32 $4.60
Average True Range (ATR) 1.16 0.18
MACD -0.45 0.04
Stochastic Oscillator 1.98 67.81

Price Performance

Historical Comparison
UVE
ABUS

About UVE UNIVERSAL INSURANCE HOLDINGS INC

Universal Insurance Holdings Inc is an insurance holding company. Through its subsidiaries, the company mainly offers property and casualty insurance and value-added insurance services. It develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners lines of business and performs all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The group offers the following types of personal residential insurance: homeowners, renters/tenants, condo unit owners, and dwelling/fire, through an independent agent network and online distribution channels across multiple states in the United States of America.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: